GrayMatters Health
- Company typePrivate
- Founded2019
- HeadquartersHaifa, Israel
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
GrayMatters Health firmographics
Firmographics- Name
- GrayMatters Health
- Legal name
- GrayMatters Health
- Website
- https://graymatters.health
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
GrayMatters Health industry classification
Industry- Product category
- Digital Therapeutics / Interventional Psychiatry Neuromodulation Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Physicians, Mental Health Specialists (621112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Services-Health Services (8000)
- akta.pro primary industry
- Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
Keywords
Where GrayMatters Health is headquartered
LocationHeadquarters
- HQ city
- Haifa
- HQ country
- Israel
- HQ region
- Middle East
Markets served
GrayMatters Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Prism Device/System Sales: Sale of Prism hardware systems to interventional psychiatry clinics. The system is stored on clinic shelves and administered by technicians. Includes Prism platforms for PTSD and depression protocols.
- Clinical Support Services: Onsite installation, training, and ongoing support services for clinic implementation. Prism360 provides operational readiness, benefits investigation, and financing support for clinics.
- Prism Pathway Program: Ongoing support program to build and maintain successful Prism programs at clinics, likely generating recurring service revenue.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
GrayMatters Health product offering
Product offeringCore offering
GrayMatters Health develops and sells the Prism Suite, an FDA 510(k)-cleared digital brain biomarker intervention system for interventional psychiatry clinics. The system uses fMRI-informed digital biomarkers and EEG cap sensors to enable patients to self-regulate brain activity associated with PTSD (amygdala-based protocol) and depression (Ventral Striatum-based protocol), and is complemented by Prism360, a clinic support service providing financing, benefits investigation, and operational readiness.
Product overview
GrayMatters Health offers the Prism Suite as its core product—a comprehensive interventional psychiatry platform powered by fMRI-informed digital biomarkers. The suite includes distinct protocols for PTSD (using amygdala-based biomarkers) and Depression (using reward-system/Ventral Striatum biomarkers). Prism360 is a supplementary support module providing financing, benefits investigation, and operational readiness services for clinics deploying the technology. The products work together to enable personalized mental health treatment through self-neuromodulation.
Differentiator
Problem solved
Functional benefit
Brands
- Prism Suite: An interventional psychiatry suite of solutions powered by fMRI-informed digital biomarkers for personalized patient care, featuring protocols for PTSD and Depression.
- Prism360
- Prism
Products and services
- Prism Suite An interventional psychiatry suite of solutions powered by fMRI-informed digital biomarkers for personalized patient care, featuring protocols for PTSD and Depression that enable patients to learn to regulate brain activity associated with their mental health conditions. Sold to interventional psychiatry clinics.
- Prism360 A support tool for interventional psychiatry clinics offering Prism for PTSD and depression, providing financing, benefits investigation, and operational guidance to support clinic adoption.
- Prism for PTSD Uses an amygdala-based biomarker and engaging computer simulation to help improve symptoms of post-traumatic stress disorder. Patients learn self-neuromodulation techniques to regulate brain activity in clinical settings.
- Prism Suite Depression Protocol FDA 510(k)-cleared digital brain biomarker intervention for depression using a reward-system (Ventral Striatum-based) biomarker, enabling patients to up-regulate brain activity to address depression symptoms, particularly anhedonia.
Quantifiable outcome
- 10,000 Prism PTSD patient sessions completed with significant clinical benefits and mild side effects
- +1 more outcomes
Companies that use GrayMatters Health
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles1 record
GrayMatters Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
GrayMatters Health partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Five Expert AdvisorscoreGrayMatters Health appointed five expert advisors to support the commercial growth of its Prism product. These advisors bring expertise in interventional psychiatry and mental health treatment, specifically supporting the FDA 510(k)-cleared digital brain biomarker intervention for PTSD and depression.
- McLean HospitalcoreMcLean Hospital, a psychiatric hospital affiliated with Harvard Medical School, was mentioned as a potential collaboration partner for future studies in digital neuromodulation therapeutics for mental disorders. The partnership aims to advance research in treatment-resistant mental health conditions.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
GrayMatters Health competitors and assessment
Company assessmentEmerging players
- Limbic: AI-driven digital mental health platform supporting self-referral and therapy matching for NHS and private mental health providers. Emerging player addressing the patient-facing front door to mental health services that could intersect with Prism's referral pathways.
- MindMaze: Digital neurotherapy company combining neuroscience, AI, and gamified康复 for neurological and psychiatric conditions. Emerging player with overlapping EEG/neurofeedback technology stack and clinic-deployed business model.
- Wave Neuroscience: Neurotechnology company using EEG-guided personalized neurostimulation for conditions including PTSD and TBI. Emerging player applying EEG biomarkers to interventional mental health treatment, similar technology stack to Prism.
- Soterix Medical: Medical device company specializing in non-invasive brain stimulation and neuro-monitoring (tDCS, tACS, HD-tDCS, EEG). Emerging player with overlapping EEG-based clinical hardware used in interventional psychiatry and neurology research.
Direct peers
- Click Therapeutics: Prescription digital therapeutics company with FDA-clearance pipeline across migraine, depression, and other indications. Direct peer developing software-based, clinically validated interventions in mental and neurological health.
- Akili Interactive: Digital therapeutics company developing FDA-cleared software-based cognitive and mental health interventions (e.g., EndeavorRx for ADHD, adult ADHD product). Direct peer as a publicly-traded DTx company pursuing FDA clearance for prescription digital therapeutics in behavioral health.
- Pear Therapeutics: Pioneer in prescription digital therapeutics for mental health and substance use disorder (reSET, reSET-O). Direct peer in DTx-for-psychiatry category; useful as a cautionary comparable on commercial scaling of prescription DTx in behavioral health.
- Big Health: Digital therapeutics company behind Sleepio (insomnia) and Daylight (anxiety), both prescribed via clinicians and reimbursed by payors. Direct peer in mental health DTx targeting anxiety and depression comorbidities that overlap with GrayMatters' PTSD/depression focus.
Broad incumbents
- Neuronetics: Commercial-stage NeuroStar TMS device maker targeting psychiatrists and mental health clinics for treatment-resistant depression. Broad incumbent competing for the same interventional psychiatry clinic budgets as Prism.
- Brainsway: Commercial-stage medical device company offering Deep TMS systems cleared for depression, OCD, and other psychiatric indications. Broad incumbent in the same interventional psychiatry clinics that GrayMatters targets with Prism.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
GrayMatters Health social profiles
Digital presenceGrayMatters Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
GrayMatters Health leadership team
Management profileNumber of profiles
Profiles6 records
GrayMatters Health funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GrayMatters Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GrayMatters Health
What does GrayMatters Health do?
GrayMatters Health develops and sells the Prism Suite, an FDA 510(k)-cleared digital brain biomarker intervention system for interventional psychiatry clinics. The system uses fMRI-informed digital biomarkers and EEG cap sensors to enable patients to self-regulate brain activity associated with PTSD (amygdala-based protocol) and depression (Ventral Striatum-based protocol), and is complemented by Prism360, a clinic support service providing financing, benefits investigation, and operational readiness.
Is GrayMatters Health a public or private company?
GrayMatters Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was GrayMatters Health founded?
GrayMatters Health was founded in 2019. It employs 1 to 10 people.
Where is GrayMatters Health based?
GrayMatters Health is headquartered in Haifa, Israel, in the Middle East region.
How does GrayMatters Health make money?
Three revenue lines are on record. Prism Device/System Sales are the primary driver. The others are clinical Support Services and prism Pathway Program.
Who are GrayMatters Health's main competitors?
Emerging players on record are Limbic, MindMaze, Wave Neuroscience and Soterix Medical. Direct peers are Click Therapeutics, Akili Interactive, Pear Therapeutics and Big Health. Broad incumbents are Neuronetics and Brainsway.
Does GrayMatters Health have an API?
No public API is recorded for GrayMatters Health.
What industry is GrayMatters Health in?
GrayMatters Health's product category is Digital Therapeutics / Interventional Psychiatry Neuromodulation Devices. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 334510 and its SIC code is 3845.